Every 8-K that McKesson Corporation (MCK) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow MCK and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MCK filings page.
McKesson Corporation entered a definitive agreement with CD&R to acquire Option Care Health, Inc. for $32.05 per share, reflecting an approximately $5.8 billion total enterprise value. The transaction value represents an approximately 37% premium to Option Care Health’s closing share price on October 5, 2026.
Under the agreement, McKesson will invest approximately $1.4 billion for an approximately 49% minority interest; CD&R will hold an approximately 51% majority interest. The transaction is expected to close in the first half of calendar year 2027, subject to customary closing conditions, including Option Care Health stockholder approval and required regulatory approvals. The agreement also establishes a framework for McKesson’s future acquisition of CD&R’s interest, subject to specified conditions and regulatory approvals.
After closing, McKesson intends to account for its interest using the equity method, recording its share of Option Care Health’s net income or loss in Other Income, net. Option Care Health will remain a separate company led by its own management team and become privately held, with its common stock no longer publicly listed on Nasdaq upon completion. Option Care Health expects to release third-quarter results on November 4, 2026, and is withdrawing its previously disclosed financial guidance.
McKesson Corporation (MCK) reported that on August 25, 2026 it discovered a cybersecurity incident affecting its information systems. The investigation is in its early stages, and additional information and updates are being made available on the company’s website at www.mckesson.com/cybersecurity.
As of this report, McKesson states it has not determined that the incident is material or that it has had, or is reasonably likely to have, any material impact on the company, including its financial condition or results of operations.
McKesson Corporation reported strong fiscal 2027 first‑quarter results with consolidated revenues of $105.4 billion, up 8% year over year, led by growth in the North American Pharmaceutical and Oncology & Multispecialty segments. GAAP diluted EPS was $5.15 versus $6.25, reflecting a $293 million redemption value adjustment tied to selling a 13% minority interest in Medical‑Surgical Solutions to Apollo Funds and other noncontrolling interest remeasurements.
Underlying performance was notably stronger on an adjusted basis. Adjusted Earnings per Diluted Share rose 20% to $9.93, driven by segment growth and a lower share count. The company returned $2.6 billion to shareholders, including $2.5 billion of share repurchases, and its board approved a 15% dividend increase to $0.94 per share, the tenth consecutive annual raise.
McKesson raised its fiscal 2027 outlook, guiding Adjusted EPS to $44.20–$45.00, implying 13%–15% growth, and continued advancing the planned separation of Medical‑Surgical Solutions, including a $1.25 billion minority sale, a $2.25 billion Term Loan B facility, and branding the future standalone business as Wellverse. Free cash flow was negative $372 million as operating cash outflows and investment exceeded inflows.
McKesson Corporation held its Annual Meeting of Shareholders on July 22, 2026. Shareholders elected 11 director nominees, including Dominic J. Caruso (93,233,995 votes for, 1,284,036 against) and Kathleen Wilson-Thompson (94,095,670 for, 434,360 against), with additional broker non-votes reported for each nominee.
Shareholders ratified the appointment of Deloitte & Touche LLP as independent registered public accounting firm for the fiscal year ending March 31, 2027, with 95,066,170 votes for and 9,872,183 against. They also approved, on an advisory basis, the compensation of the named executive officers, with 86,580,776 votes for, 7,732,776 against, and 387,199 abstentions.
McKesson Corporation reported an upcoming leadership change in its strategy organization. On June 29, 2026, Executive Vice President and Chief Strategy and Business Development Officer Thomas L. Rodgers, a named executive officer, gave notice of his intention to retire from that role, with his last day of employment on August 1, 2026.
To support an orderly transition, McKesson appointed Ramesh Srinivasan as Executive Vice President, Chief Strategy Officer, effective August 1, 2026. The company framed this as a planned retirement with a designated successor to maintain continuity in its strategy leadership.
McKesson Corporation reports that certain subsidiaries, including McKesson Medical-Surgical Top Holdings, entered into an amendment to their credit agreement to provide a new $2,250.0 million senior secured Term B loan facility due 2032.
The Term B Loan Facility bears interest at the borrower’s option at either the Adjusted Term SOFR Rate plus 2.25% per year or the Base Rate plus 1.25% per year, with an initial selection of the SOFR-based option. The facility is secured by substantially all tangible and intangible assets of the borrower and certain material U.S. subsidiaries, which act as guarantors.
The credit agreement includes financial covenants, including a maximum total net leverage ratio and a minimum interest coverage ratio, both with customary cure rights. Other terms of the underlying credit agreement remain substantially the same except for changes made by this amendment.
McKesson Corporation reported strong fourth quarter and fiscal 2026 results, raised capital returns, and issued upbeat guidance. Full-year consolidated revenues were $403.4 billion, up 12%, while earnings per diluted share rose to $38.38 from $25.72. Adjusted Earnings per Diluted Share reached $39.11, an 18% increase, above the company’s previously communicated long-range growth targets.
Free Cash Flow was $5.4 billion, and McKesson returned $5.1 billion to shareholders through $4.8 billion of share repurchases and $381 million of dividends. The board added $5.0 billion to the share repurchase program, bringing authorization to $7.7 billion, and the company entered a $2.25 billion accelerated repurchase. For fiscal 2027, McKesson set Adjusted Earnings per Diluted Share guidance of $43.80 to $44.60, implying 12% to 14% growth, and reaffirmed its long-term adjusted EPS growth target of 13% to 16%.
McKesson Corporation entered into a new senior unsecured revolving credit agreement providing a $5.0 billion credit line maturing in April 2031. This New Revolving Credit Facility replaces the company’s prior $1.0 billion 364‑day facility and $4.0 billion five‑year facility.
The facility includes a $4.5 billion sublimit for borrowings in Canadian Dollars, British Pound Sterling and Euros and a financial covenant capping total debt to Consolidated EBITDA at 4.25x, with a temporary step‑up to 4.75x after certain cash acquisitions of at least $500 million.
McKesson Corporation disclosed that subsidiaries, led by McKesson Medical-Surgical Top Holdings, entered into new senior secured credit facilities totaling $2.0 billion. These include a $750.0 million Term Loan A-1 due 2031, a $250.0 million Term Loan A-2 due 2028, and a $1,000.0 million revolving credit facility maturing on April 1, 2031.
The term loans initially bear interest at the Adjusted Term SOFR Rate plus 1.250% per year, while revolving borrowings initially bear interest at the Term Benchmark Rate plus 1.250% or the Base Rate plus 0.250%, with margins later varying based on leverage and credit ratings. The facilities are secured by substantially all tangible and intangible assets of the borrower and certain U.S. subsidiaries and include customary covenants and financial tests on leverage and interest coverage.
McKesson Corporation filed an 8‑K to share investor relations updates. The company will release its fourth quarter fiscal 2026 results after market close on May 7, 2026, followed by an earnings conference call and live webcast at 4:30 PM Eastern Time.
Chief Executive Officer Brian Tyler and Chief Financial Officer Britt Vitalone will host the call. McKesson also reaffirmed its fiscal 2026 full year outlook, consistent with guidance issued on February 4, 2026, and highlighted Mr. Vitalone’s participation in several major healthcare investor conferences, with webcasts available on its investor relations website.
McKesson Corporation announced a planned chief financial officer transition, with longtime CFO Britt J. Vitalone retiring and Kenny K. Cheung appointed as the new Executive Vice President and Chief Financial Officer.
Vitalone will step down as CFO on May 28, 2026, remain an employee through July 1, 2026, and then serve as a non‑employee advisor under an agreement providing a $50,000 monthly advisory fee. Cheung, age 44, joins from Sysco, where he was Executive Vice President and CFO, and previously held senior finance roles at Hertz, Nielsen and General Electric.
In connection with his appointment, Cheung will receive a one‑time $3,500,000 sign‑on cash bonus, sign‑on restricted stock units with a grant date value of $6,000,000, an annual base salary of $1,050,000, a target annual bonus opportunity equal to 125% of eligible earnings, performance stock units for the fiscal years 2027–2029 with a grant date value of $3,450,000, and additional restricted stock units with a grant date value of $2,300,000.
McKesson Corporation filed a current report to furnish its preliminary financial results for the quarter ended December 31, 2025. The company states that these preliminary results are provided in an earnings release attached as Exhibit 99.1.
The report clarifies that the earnings information, including Exhibit 99.1, is being furnished to the SEC rather than filed, which affects how it may be used under certain securities law provisions. The filing is signed on behalf of McKesson by its Executive Vice President and Chief Financial Officer, Britt J. Vitalone.
McKesson Corporation furnished preliminary results for the quarter ended September 30, 2025. The company provided these results in an earnings release attached as Exhibit 99.1, dated November 5, 2025. The information is being furnished to the SEC and is not deemed filed under the Exchange Act.
McKesson Corporation filed a current report to highlight its Investor Day and an accompanying news release that updates Fiscal 2026 guidance and long-term targets. The company is hosting its Investor Day, beginning at 9:30 a.m. Eastern time, with a live webcast and archived replay available through its investor relations website. The related news release is provided as Exhibit 99.1 and, along with this item, is being furnished to the SEC rather than filed, meaning it is not automatically incorporated into other securities law filings unless specifically referenced.
McKesson Corporation is changing how it reports its business, moving to four reportable segments starting in the second quarter of fiscal 2026: North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions, and Medical-Surgical Solutions. Norwegian operations will be reported in an "Other" category, alongside Corporate activities.
The North American Pharmaceutical segment will combine wholesale drug distribution in the United States and Canada. Oncology & Multispecialty will group specialty provider solutions, practice management services, multispecialty providers, clinical trial services, and specialty pharmacy offerings. Prescription Technology Solutions will focus on technology-enabled networks that connect patients and healthcare stakeholders to improve medication access and affordability. Medical-Surgical Solutions will continue to serve alternate sites of care, and McKesson previously announced its intention in May 2025 to separate this segment into an independent company.
McKesson has also entered into a definitive agreement, dated August 4, 2025, to sell its Norwegian distribution and retail businesses, subject to customary closing conditions and regulatory approvals. To help investors understand the impact of the new reporting structure, the company is providing supplemental historical financial information by new segment for selected fiscal 2024 and 2025 quarters and for the fiscal years ended March 31, 2025 and 2024.
McKesson Corporation (MCK) filed a Current Report on Form 8-K dated August 6, 2025. The Company states it furnished its preliminary results for the quarter ended June 30, 2025, which are attached as Exhibit 99.1 (earnings release). The filing clarifies that the information, including Exhibit 99.1, is furnished to the SEC and shall not be deemed "filed" under Section 18 of the Exchange Act or incorporated by reference except by specific reference.
Key filing details:
- Report date: August 6, 2025
- Exhibits filed: 99.1 (earnings release) and 104 (iXBRL cover page)
- Signed by: Britt J. Vitalone, Executive Vice President and Chief Financial Officer
- Securities listed on NYSE: Common stock (MCK), 1.500% Notes due 2025 (MCK25), 1.625% Notes due 2026 (MCK26), 3.125% Notes due 2029 (MCK29)
McKesson Corporation (NYSE: MCK) filed an 8-K summarizing the 30 July 2025 Annual Meeting results (Item 5.07).
- All 12 director nominees were re-elected; support exceeded 95% of votes cast, with only ~0.9-4.7 m "against" votes and 10.3 m broker non-votes per nominee.
- Shareholders ratified Deloitte & Touche LLP as independent auditor for FY 2026 by a 92% majority (102.2 m for / 8.6 m against / 0.1 m abstain).
- The advisory say-on-pay proposal also passed with ~92% approval (91.8 m for / 8.0 m against / 0.8 m abstain).
No additional business, strategic announcements or financial guidance were disclosed. The outcome signals continued investor confidence in board composition, executive pay and audit oversight but carries limited immediate valuation impact.